

Fig. 1 a




Fig. 1 b




Fig. 1: Model of a complete IgG molecule and Fab fragment; C constant, V variable, CDR complementarity determining regions,

BEST AVAILABLE COPY

16/522596




Fig. 2: Expression cassette of huFab vector. CDR: complementarity determining region; C: constant light or constant heavy domain; FR: framework region; peIB: leader sequence; pIII: phage protein pIII; SD: Shine-Dalgarno sequence;  $V_H$ : variable heavy domain;  $V_L$ : variable light domain

FIG. 2

BEST AVAILABLE COPY

10/02209

3/20




Fig. 3




Fig. 4  
"naive" library

structure-plexing:  
recombination by ...

$V_L \times V_H$  shuffling

$[V_L - V_H \text{CDR1-2}] \times \text{HCDR3} \approx 10^{14} \pm$

$\downarrow C^1 C^2$

$V_L \times \text{plexed } V_H \approx 10^{21} \pm$

$\Sigma: 7 \times 10^{17}$

$5 \times 10^9$  operative library

BEST AVAILABLE COPY

10/522596

4/20

footnote to figures 3 and 4:

‡ theoretically accessible library size; \* real size of unplexed library; § initial complexity of V<sub>H</sub> library subsets

For cosmix-plexing@ the first restriction enzyme used must generate non-palindromic extensive-ends.

The resolution sites in FR3 of V<sub>H</sub> (site B<sup>1</sup>, B<sup>2</sup>, and B<sup>3</sup> in Fig. 3 and 4) are for three different restriction enzymes (B<sup>1</sup> = *Spe*I for Kabat subgroup V<sub>H</sub>1, B<sup>2</sup> = *Hind*III for subgroup V<sub>H</sub>2; and B<sup>3</sup> = *Xho*I for Kabat subgroup V<sub>H</sub>3. This and a characteristic overhang following a *Sap*I restriction at site A between heavy and light chain enable conservation of the respective functional framework context.

BEST AVAILABLE COPY

5/20




Figure 5

Structure-plexing protocol ensuring high efficiency recombination restricted to within each of the three V<sub>H</sub> framework subgroups: In step 1, circular phagemid DNA from the library is cleaved by the type IIs restriction enzyme SspI, which creates a unique non-palindromic cohesive end, which is unique for each V<sub>H</sub>-framework group. Step 2: When these cleavage products are ligated at high DNA concentration, three sets of concatamers are formed, as shown, each containing only members from the same framework group. Step 3: A second cleavage with the framework group-specific restriction enzymes (SspI, HindIII and XhoI) leads to resolution of the recombination products, i.e. monomeric units are formed which on ligation at low DNA concentration (Step 4) form, by ring closure, phagemid vectors, which have the same general structure as the starting plasmids, but in which the V<sub>H</sub> CDR3s have been recombined with V<sub>H</sub>-(CDR1+2) variants from other clones. All these reactions can be carried out within a "one pot" reaction without purification of any fragments. Furthermore, it should be noted that during recombination the V<sub>H</sub>-CDR3 region remains with the same light chain, a feature which we consider important at early stages when working with large numbers of preselected variants, in order to maintain structural schema. If required entire light and heavy chains can be reshuffled after SfiI and AscI cleavage (not shown in the diagram) with or without the formation of concatamers and their resolution. Variants and recombinants illustrated are shown as single representatives of much larger series

10/522594

FIG. 6




Figure 7




Figure 6: Primers used for the first PCRs of light and heavy chains.

Figure 7: Primers used for the second PCRs of light and heavy chains, introducing the required restriction sites and the VH subgroup-specific SapI sites. SapI was introduced by amplifications using the indicated AscSap-containing sense primers and the non-sense primer 3'vNhe-. The resulting product was used as mega-primer in an amplification with the primer HUISfi+. The product was cloned after SfiI and NheI digestion. Light chain sequences were cloned using SfiI and AscI. Heavy chain fragments were cloned using either NheI and BclI, HindIII, XhoI for 5' fragments, or MluI and BclI, HindIII, XhoI for the 3' fragments.

BEST AVAILABLE COPY

7/20




Fig. 8

footnote:

A: Recombination via structure-plexing as in Fig. 3

B: Selection round(s)

Further naive and/or selected clones (1, 2 and/or 3) can be subjected to another round of structure-plexing.

BEST AVAILABLE COPY

10/522593

Forward and back primer to introduce a restriction site into FR3 of subgroup VHI:

mostly: AGG GTC ACC ATG ACC AGG GAC AGC TCC ATC AGC ACA GCC TAC ATG GAG CTG AGG AGG CTG AGA TCT GAC GAC ACN GAY TAT TGT GCG AGG  
ambig. CGN GTN ACN ATG ACN CGN GAY ACN WSN ATH WSN ACN GCN TAY ATG GAR YTN WSN CGN YTN CGN GAY GAY ACN GCN GTN TAY TAY TGY GCN CGN

ACT AGT

SpeI

C ACC ATT ACC GCG GAC ACT AGT TTCCTTCT 3'

3' g Tgg TAA Tgg Cgc CTg Tga TCA AAggAaga 5' H1FR3Spe-

mostly: AGG GTC ACC ATG ACC AGG GAC AGC TCC ATC AGC ACA GCC TAC ATG GAG CTG AGG AGG CTG AGA TCT GAC GAC ACN GAY TAT TGT GCG AGG  
ambig. CGN GTN ACN ATG ACN CGN GAY ACN WSN ATH WSN ACN GCN TAY ATG GAR YTN WSN CGN YTN CGN GAY GAY ACN GCN GTN TAY TAY TGY GCN CGN

SpeI

5' CCAACCAA ACT AGT ACR AGC ACA GCC TAC ATG G 3' FR3H1Spe+

FR3H1Spe+

8/20

Fig.9

BEST AVAILABLE COPY



**Forward and back primer to introduce a restriction site into FR3 of subgroup VIIII:**

	R	V	T	I	S	V	D	K	S	K	N	Q	F	S	L	K	L	S	S	V	T	A	A	D	T	A	V	Y	Y	C	A	R
mostly:	CGA	GTC	ACC	ATA	TCA	GTA	GAC	AAG	TCC	AAG	AAC	CAG	TTC	TCC	CTG	AAG	CTG	AGC	TCT	GTG	ACC	GCC	GCG	GAC	ACG	GCC	GTG	TAT	TAC	TGT	GCG	AGI
ambig:	CGN	GTN	ACN	ATH	WSN	GTN	GAY	AAR	WSN	AAR	AAV	CAR	TTY	WSN	YTN	AAR	YTN	WSN	WSN	GTN	ACN	GCN	GCN	GAY	ACN	GCN	GTN	TAY	TAY	TGY	GCN	CGN

**AAG CTT**

## BindII

C CAG TTC TCC CTG AAG CTT TTATTATA 3'

3' g gTC AAg Agg gAC TTC gAA AATAATAT 5' H4FR3Hind-

H4FR3Hind-

[illegible]

**AAG CTT**

## HindIII

5' CCAACCAA AAG CTT AGC TCT GTG ACC GCC GCR 3' FR3H4HimD+

FR3H4HnD+

9/20

FIG. 9 continued

**BEST AVAILABLE COPY**

10/522596

Forward and back primer to introduce a restriction site into FR3 of subgroup VHIII:

mostly: CGA TTC ACC ATC TCC AGA GAC AAC GCC AAG AAC TCA CTG TAT CTG CAA ATG AAC AGC CTG AGA GCC GAG GAC ACG GCT GTG TAT TAC TGT GCG AGT  
ambig.: CGN TTY ACN ATH WSN CGN GAY AAY GCN AAR AAY WSN YTN TAY YTN CAR ATG AAY WSN YTN CGN GCN GAR GAY ACN GCN GTN TAY TAY TGY GCN CGT

CT CGA G

XhoI

ggc CGA TTC ACC ATC TCT CGA GTTATTATA 3'

3' CCg gCT AAg Tgg Tag AgA gCT CAATAATAT 5' H3FR3Xho-

mostly: CGA TTC ACC ATC TCC AGA GAC AAC GCC AAG AAC TCA CTG TAT CTG CAA ATG AAC AGC CTG AGA GCC GAG GAC ACG GCT GTG TAT TAC TGT GCG AGT  
ambig.: CGN TTY ACN ATH WSN CGN GAY AAY GCN AAR AAY WSN YTN TAY YTN CAR ATG AAY WSN YTN CGN GCN GAR GAY ACN GCN GTN TAY TAY TGY GCN CGN

CT CGA G

XhoI

CCAACCAA TCT CGA GAY AAT KCC AAG AAC WC FR3H3Xho+

10/20

Fig. 9 continued

BEST AVAILABLE COPY

10/522596

11/20




Fig. 10 a




Fig 10 b

BEST AVAILABLE COPY

12/20

Figure 11:

huFab -pro- selections on hVEGF

Numbers of input and resulting phages and the applied conditions of selection are shown.

Panning No.	phage from round	beads	blocker	buffer		phage input	phage output
				incubation	wash / x-times/total time		
1-pro-	naive library	Carboxy	100 mM ethano-lamine	0.001% PBST in 1% fishge-latine	PBST 0.001 % Tween 10x within 35 min	1x 10 <sup>12</sup> cfu	3.8x 10 <sup>4</sup> cfu
structure plexing <sup>®</sup> : without LC* shuffling: 6.6 x10 <sup>8</sup> new variants; with LC shuffling: 3.3 x10 <sup>8</sup> new variants							
1-pro- after plexing	from plexing	Carboxy	100 mM ethano-lamine	2YT + 0.01 % Tween	PBST 0.05% Tween 12 x within 45 min	2x 10 <sup>11</sup> cfu	2.1 x 10 <sup>6</sup> cfu

\* LC: light chain

BEST AVAILABLE COPY

13/20

Figure 12:  
huFab -pro- selections on hIGF  
Numbers of input and resulting phages and the applied conditions of selection are shown.

Panning No.	phage from round	beads	blocker	buffer		phage input	phage output
				incubation	wash / x-times/total time		
1-pro-	naive library	Carboxy	100 mM ethano-lamine	0.001% PBST in 1% fishge-latine	PBST 0.001 % 10x within 35 min	1x10 <sup>12</sup> cfu	7 x 10 <sup>4</sup> cfu
cosmix-plexing <sup>®</sup> : without LC* shuffling: 3.8 x 10 <sup>8</sup> new variants; with LC shuffling: 5.5 x10 <sup>7</sup> new variants							
1-pro- after plex-ing	from plex-ing	Carboxy	100 mM ethano-lamine	2YT + 0.01 % Tween	PBST 0.05% Tween 12 x within 45 min	2x 10 <sup>11</sup> cfu	1.5x 10 <sup>7</sup> cfu

\* LC: light chain

BEST AVAILABLE COPY


2004013328

14/20

FIG. 13a

# **Selections on:**

**1<sup>st</sup> selection**  
(from ca  $10^{12}$ )



**structure-plexing®:**

**new variants**

BEST AVAILABLE COPY

Figure 13b

Phage production from new variants




selection round on respective target:  
(challenge with  $2 \times 10^{11}$  particles)

hVEGF

hIGF

$2.1 \times 10^6$  cfu

$1.5 \times 10^7$  cfu



positives\* after

selection, structure

plexing® + selection:

11

11

positives\* after 2 rounds

of selection without

structure plexing®:

2

9

From 60 chosen randomly: \* Positives = Abs.  $\geq 0.500$  in phage ELISA and  $\geq 5$  fold  
over background

10/522596

16/20

Target: human VEGF

# hVEGF phage-ELISA (021031)




Figure 14

BEST AVAILABLE COPY




10/52259

17/20

Figure 15


# Target: human insulin-like growth factor



BEST AVAILABLE COPY


Figure 16

# Protein production and purification



19/20

Figure 17  
Affinity analysis of interaction between  
huFab and huVEGF



Affinity constants

$K_D = 120 \text{ nM}$


$R_{\max} = 606 \text{ RU}, X^2 = 9$

Rate Equation: 1:1 langmuir binding

$$\frac{dR}{dt} = k_a \times C \times (R_{\max} - R) - k_d \times R$$

BEST AVAILABLE COPY

Figure 18  
Affinity analysis of interaction between the huFab protein and hIGF (immobilised)



Rate Equation: 1:1 langmuir binding

$$\frac{dR}{dt} = k_a \times C \times (R_{\max} - R) - k_d \times R$$

Affinity constants

$$K_D = 10 \text{ nM}$$

$$R_{\max} = 207 \text{ RU}, \quad X^2 = 10$$